Healthcare / BiotechnologyNasdaqCM
$16.87
+2.41 (+16.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.3M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$89M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.5%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3474.7%
FCF / Net income
3.32x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $858000.0 · net income $-9.0M · FCF $-29.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $858000.00 | $858000.00 | $636000.00 | — | — | — | — |
| Net Income | $-9.0M | $-9.0M | $-57.8M | $-74.6M | $-66.7M | $-47.0M | $-26.4M |
| EBITDA | $-33.0M | $-33.0M | $-60.4M | $-78.8M | $-67.7M | $-45.5M | $-25.2M |
| EPS | -1.59 | -1.59 | -10.64 | -14.72 | -16.72 | -14.72 | — |
| Operating Margin | -3853.6% | -3853.6% | -9511.9% | — | — | — | — |
| Net Margin | -1046.4% | -1046.4% | -9084.1% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Current Ratio | 12.92 | 12.92 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-29.8M | $-29.8M | $-49.3M | $-60.3M | $-57.3M | $-45.9M | $-22.2M |
| Returns | |||||||
| ROE | -15.5% | -15.5% | -93.7% | -70.2% | -39.4% | -26.8% | -19.4% |
| Valuation | |||||||
| P/B | 1.64 | 1.64 | 0.71 | 0.81 | 1.15 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 34.9% | 34.9% | — | — | — | — | — |
| EPS Growth | 85.1% | 85.1% | 27.7% | 12.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+582.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-10.64 → -1.59
Residual
+582.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.